Cannabis for medicinal use encounters export barriers: Analdex

“Factors like geographic position, variety of thermal floors, tropical location, low harvest costs and optimal growing conditions make cannabis for Colombian medicinal use possible be very prominent in the world. However, there needs to be greater speed and willingness from the government for medical cannabis to become a relevant player in the quest to diversify the country’s basket of exports,” the union leader said.

According to diego ruizDirector of Regulatory Affairs at FCM Global, a company that produces and exports cannabis oils, extracts and isolates to Peru, Ecuador, Brazil, Argentina, Germany, Belgium, United Kingdom and Uruguaysaid that “the government is focusing on the export of dried flowers and seeds, but others, such as phytotherapeutics, are left behind.”

The businessman added that “the delays in registrations with the Invima, as well as the delay in the National Narcotics Fundthat take between 2 and 3 months to approve an export certificate for phytotherapeutic products are situations that have caused significant losses for the sector”.

Analdex indicates that the industry’s rise in exports in recent years shows an increase of more than 3,000% in external sales between 2019 and 2022.

Last year, the country showed a positive variation of 89.1% from 2021 and reached total exports of 9.6 million, according to figures from the Deen and ProColombia. However, it is far from the forecasts that the exporting companies had.

2021, the Ministry of Health, together with the Ministry of Justice and Agriculturegenerated the roadmap for cannabis regulated by Decree 811 of 2021 and Resolution 227 of 2022, to emphasize the industrial use, use in food and beverages, the export regime and allow external sale of the flower for medicinal use.

Source: El heraldo